Zhao Tengda, Wang Xueping, Fu Liwu, Yang Ke
Department of Oral and Maxillofacial Surgery, Department of Health Management Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.
Sun Yat-sen University Cancer center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China.
Cancer Drug Resist. 2022 May 12;5(2):436-450. doi: 10.20517/cdr.2021.144. eCollection 2022.
A dysbiosis in microbial diversity or functionality can promote disease development. Emerging preclinical and clinical evidence emphasizes the interplay between microbiota and both disease evolution and the treatment response of different cancers. One bacterium that has garnered much attention in a few cancer microbiota studies is (Fn). To provide updated knowledge of the functional role of Fn in cancer prevention and management, this review summarizes the relationship among Fn, cancer, and chemoimmunotherapy response, with the potential mechanisms of action also intensively discussed, which will benefit the development of strategies to prevent or treat cancer via Fn-based therapeutic interventions.
微生物多样性或功能的失调会促进疾病发展。新出现的临床前和临床证据强调了微生物群与不同癌症的疾病演变和治疗反应之间的相互作用。在一些癌症微生物群研究中备受关注的一种细菌是具核梭杆菌(Fn)。为了提供关于Fn在癌症预防和管理中的功能作用的最新知识,本综述总结了Fn、癌症和化学免疫治疗反应之间的关系,并深入讨论了潜在的作用机制,这将有助于通过基于Fn的治疗干预措施制定预防或治疗癌症的策略。